Long Term Metastasis-Free Survival in Stage IV anal Melanoma Cured by Repetitive Surgery and Short Cycle of Adjuvant Ipilimubab

Francesco Tonelli*

Department of Experimental and Clinical Medicine, University of Florence, Italy

^*Correspondance to: Francesco Tonelli 

 PDF  Full Text DOI: 10.25107/2474-1647.2849

Abstract

Anal melanoma is often advanced at time of diagnosis and despite curative surgery no 5 year diseasespecific survival has been observed when distant metastasis have been developed. In June 2011 at 69 years old male affected by anal melanoma was submitted to local excision of the neoplasia. At the follow-up no local recurrence was observed in the anal canal, but iterative metastases occurad at the right retroperitoneum (January 2014), at the left adrenal gland (October 2014), at the left gluteal region (September 2015), and at the first jejunal loop (March 2016) that every time were removed by surgery. On May 2016 the patient began ipilimubab at a dose of 10 mg per kg every 3 weeks for a total of 4 doses. To date (May 2020, 9 years after the diagnosis) the patient is free from disease. This experience confirms the important role of surgical resection of metastases from anal melanoma and the value of adjuvant treatment with immunotherapy for maintaining the result achieved by radical surgery.

Keywords

Cite the article

Tonelli F. Long Term Metastasis-Free Survival in Stage IV anal Melanoma Cured by Repetitive Surgery and Short Cycle of Adjuvant Ipilimubab. Clin Surg. 2020; 5: 2849.